Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6 at 8:30 a.m. ET.

To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. The webcast and presentation will be archived for viewing for 60 days thereafter.

About Aeglea BioTherapeuticsAeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase 1 Deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine.

For more information, please visit http://aegleabio.com.

Media Contact:
Kelly Boothe, Ph.D.
Pure Communications
415.946.1076
[e-mail]

Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
[e-mail]